Cargando…
Effects of receptor tyrosine kinase inhibitors on VEGF(165)a- and VEGF(165)b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
BACKGROUND AND PURPOSE: Receptor tyrosine kinase inhibitors (RTKIs) targeted at VEGF receptor 2 (VEGFR2) have proved to be attractive approaches to cancer therapy based on their ability to reduce angiogenesis. Here we have undertaken a quantitative analysis of the interaction of RTKIs and two VEGF s...
Autores principales: | Carter, Joanne J, Wheal, Amanda J, Hill, Stephen J, Woolard, Jeanette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459029/ https://www.ncbi.nlm.nih.gov/pubmed/25684635 http://dx.doi.org/10.1111/bph.13116 |
Ejemplares similares
-
Real-time analysis of the binding of fluorescent VEGF(165)a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
por: Kilpatrick, Laura E., et al.
Publicado: (2017) -
Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF(165)b Producing Cells
por: Afkhami, Fatemeh, et al.
Publicado: (2010) -
The splicing factor YBX1 promotes the progression of osteosarcoma by upregulating VEGF(165) and downregulating VEGF(165b)
por: Quan, Bingxuan, et al.
Publicado: (2023) -
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008) -
VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)